4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $12.00, for a total value of $19,620.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 15.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Scott Bizily also recently made the following trade(s):
- On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total transaction of $19,947.00.
- On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00.
4D Molecular Therapeutics Stock Up 19.4%
Shares of NASDAQ:FDMT traded up $2.36 during trading on Monday, reaching $14.55. The stock had a trading volume of 3,444,983 shares, compared to its average volume of 805,311. 4D Molecular Therapeutics, Inc. has a one year low of $5.97 and a one year high of $15.03. The company has a market capitalization of $760.67 million, a P/E ratio of -5.53 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $10.94 and its 200 day simple moving average is $9.89.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of FDMT. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth about $46,000. Millennium Management LLC increased its holdings in 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after buying an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd acquired a new position in 4D Molecular Therapeutics in the 1st quarter worth approximately $39,000. American Century Companies Inc. raised its position in 4D Molecular Therapeutics by 11.5% during the 2nd quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after buying an additional 5,026 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after buying an additional 2,284 shares during the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on FDMT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.62.
Read Our Latest Analysis on 4D Molecular Therapeutics
About 4D Molecular Therapeutics
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Featured Stories
- Five stocks we like better than 4D Molecular Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
